CV Lattes
ResearcherID
Universidade de São Paulo (USP). Faculdade de Ciências Farmacêuticas (FCF) (Institutional affiliation from the last research proposal) Birthplace: Brazil
graduate at Farmácia e Bioquímica from Universidade de São Paulo (1975), master's at Farmácia e Bioquímica from Universidade de São Paulo (1982) and ph.d. at Microbiology from Universidade Federal de São Paulo (1990). Has experience in Microbiology, focusing on Medical Microbiology, acting on the following subjects: staphylococcus aureus, fagotipagem, mrsa, pcr and mycobacterium tuberculosis. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Linezolid, the first agent of the oxazolidinone class to be introduced clinically, is potentially active against important bacterial pathogens, including methicillin-resistant Staphylococcus spp. and vancomycin-resistant Enterococcus spp.. This new oxazolidinone inhibits protein biosynthesis by binding to the peptidyl transferase center (PTC) of the 50S subunit of the bacterial ribosome. …
The first line of choice for the treatment of infections caused by Methicillin-Resistant Staphylococcus aureus is the antibiotic vancomycin. MRSA strains which do not respond to treatment with vancomycin can be characterized as being either resistant (VRSA) or intermediate (VISA). VISA strains present cell wall thickening as a result of a string of mutations in possibly different sets of…
Linezolid, the first agent of the oxazolidinone class to be introduced clinically, is potentially active against important bacterial pathogens, including methicillin-resistant Staphylococcus spp. and vancomycin-resistant Enterococcus spp.. This new oxazolidinone inhibits protein biosynthesis by binding to the peptidyl transferase center (PTC) of the 50S subunit of the bacterial ribosome. …
Linezolid, a synthetic antimicrobial of the oxazolidinone class, is active against important bacterial pathogens, including multi-drug resistant Staphylococcus spp and Enterococcus spp. This new oxazolidinone drug inhibits protein biosynthesis by binding itself to the peptidyl transferase center (PTC) of the 50S subunit of the bacterial ribosome. Although linezolid resistance can be media…
| 6 / 1 | Completed research grants |
| 7 / 2 | Completed scholarships in Brazil |
| 1 / 1 | Completed scholarships abroad |
| 14 / 4 | All research grants and scholarships |
| Associated processes | |